Haaartland

Login
CLVS Seeks New Use For Rubraca, TNDM Effects Reverse Stock Split, MDXG On Watch

inBrighter #Type1diabetes

CLVS Seeks New Use For Rubraca, TNDM Effects Reverse Stock Split, MDXG On Watch

Source: markets.businessinsider.com

Bo

Bo

Your sidekick
Sweden

Bo
Your sidekick

  • 0

(RTTNews) - Today's Daily Dose brings you news about AstraZeneca's lung cancer drug TAGRISSO getting Breakthrough Therapy Designation; Clovis' seeking approval for expanded indication of its ovarian cancer drug; MiMedx Group's share repurchase program and Tandem Diabetes' reverse stock split. AstraZeneca plc's (AZN) TAGRISSO has been granted Breakthrough Therapy Designation

View original